US › Healthcare

Septerna, Inc. Common Stock (SEPN)

US · Healthcare · Biotechnology

$38.98+11.44%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$26.5M
Revenue YoY
+12011.0%
Net profit
$-8.6M
Profit YoY
+59.8%
EPS
$-0.19
EPS estimate
$-0.44
Net margin
-32.6%

EPS came in at -0.19 against a street estimate of -0.44 — a beat of 56.8%.

Key statistics

Market cap
$1.55B
Forward P/E
107.5
P/B
4.11
Book value
$8.43
EPS (TTM)
$-0.80
52-week high
$38.04
52-week low
$10.62
50-day MA
$33.30
200-day MA
$27.25

Analyst view

Analysts rate Septerna, Inc. Common Stock a buy (3 buy, 1 hold, 0 sell out of 4) with an average price target of $45.00.

Shareholding

Insiders
3.17%
Institutions
102.69%

Largest institutional holders

FundStake
RA Capital Management, LLC15.52%
TRV GP V, LLC13.79%
Driehaus Capital Management LLC9.75%
TRV GP VI, LLC9.34%
Samsara BioCapital, LLC6.99%
The Goldman Sachs Group Inc6.45%
Siren, L.L.C.4.44%
BlackRock Inc4.04%

Recent filings & reports

DocumentDate
Shareholder vote results · Q2 20262026-06-30
Quarterly report · Q1 20262026-05-11
Results announced · Q2 20262026-05-11
Proxy statement · Q2 20262026-04-30
Reg FD disclosure · Q2 20262026-04-13
Annual report FY20252026-03-09
Results announced · Q1 20262026-03-09
Quarterly report · Q3 20252025-11-10

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Septerna, Inc. Common Stock — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.